Study | study type
|
Pathology | T1 | T0 | Patients | sample sizes | ROB | Results | deaths (OS) E | progression or deaths (PFS) E | RFS/DFS E | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ovarian cancer (OC) ovarian cancer (OC) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
versus Standard of Care (SoC) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rucaparib | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ARIEL4, 2022 NCT02855944 | RCT | ovarian cancer (OC) | oral rucaparib (600 mg twice daily) | chemotherapy (administered per institutional guidelines) | patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation who had received two or more previous chemotherapy regimens who had received two or more previous chemotherapy regimens | -/- | NA | safety concern | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ARIEL3, 2017 NCT01968213 | RCT | ovarian cancer (OC) | after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma | 375 / 189 | NA | suggested |